Biological activity of cadeguomycin. Inhibition of tumor growth and metastasis, immunostimulation, and potentiation of 1-.BETA.-D-arabinofuranosylcytosine.
- 1 January 1985
- journal article
- research article
- Published by Japan Antibiotics Research Association in The Journal of Antibiotics
- Vol. 38 (5) , 642-648
- https://doi.org/10.7164/antibiotics.38.642
Abstract
Cadeguomycin retarded growth of sc solid IMC carcinoma in CDF1 mice, and pulmonary metastasis of Lewis lung carcinoma in C57BL/6 mice. The antibiotic enhanced phagocytic activity of murine peritoneal macrophages and IL-1 production by P388D1 cells. Delayed type hypersensitivity was stimulated and interferon was induced by the drug. The results suggest that cadeguomycin inhibits tumor growth and metastasis in association with modification of the immune system. The cytotoxicity of arabinosylcytosine to K562 and YAC-1 cells was markedly enhanced by cadeguomycin in culture. The combined administration of arabinosylcytosine and cadeguomycin displayed potentiation in the inhibition of growth of ip-implanted P388 leukemia and metastasis of sc-implanted P388 leukemia to the regional lymph nodes. Cadeguomycin showed low toxicity for mice.This publication has 2 references indexed in Scilit:
- Cadeguomycin, a novel nucleoside analog antibiotic. I. The producing organism, production and isolation of cadeguomycin.The Journal of Antibiotics, 1982
- Effect of bestatin on mouse immune system and experimental murine tumors.The Journal of Antibiotics, 1980